An HNSCC-modified iRECIST approach is proposed in which observation is reserved for patients with clinical stability, low-risk anatomy, and feasible short-interval reassessment, and proposed mechanisms include immune-cell infiltration, inflammatory edema, tumor necrosis, increased vascular permeability, and hemorrhage.